Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MP 0533

Next Previous
Drug Profile

MP 0533

Alternative Names: AML CD3 x CD33 x CD70 x CD123 ; MP-0533; Multi-specific DARPin® T-cell engager; Multi-specific T-cell engager - Molecular Partners AG

Latest Information Update: 20 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Partners AG
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 12 Jan 2025 Efficacy data from a phase I/IIa trial in Acute myeloid leukemia (AML) or Myelodysplastic syndrome (MDS) released by Molecular Partners
  • 08 Dec 2024 Efficacy and adverse events data from a phase I/IIa trial in Acute myeloid leukemia (AML) or Myelodysplastic syndrome (MDS) released by Molecular Partners
  • 07 Dec 2024 Updated efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I/II trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top